Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsHALO -1.98%92 Cash Ratio is 0.67 as of Jun. 2026, which is 81% below its 10-year median of 3.55. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $97.09 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,378 Biotechnology companies, Halozyme Therapeutics ranks worse than 78.96% on this metric.
Halozyme Therapeutics has a Cash Ratio of 0.67. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Halozyme Therapeutics's Cash Ratio or its related term are showing as below:
HALO'
s Cash Ratio Range Over the Past 10 Years
Min: 0.67 Med: 3.55 Max: 14.78
Current: 0.67
During the past 13 years, Halozyme Therapeutics's highest Cash Ratio was 14.78. The lowest was 0.67. And the median was 3.55.
HALO's Cash Ratio is ranked worse than 78.96% of 1378
companies
in the Biotechnology industry
Industry Median: 2.96
vs HALO: 0.67
Halozyme Therapeutics (NAS:HALO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Halozyme Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a Cash Ratio of 0.67 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Halozyme Therapeutics and its competitors. This is 81% below median its historical median of 3.55. Over the past decade, Halozyme Therapeutics' Cash Ratio has ranged from 0.67 to 14.78. According to the industry distribution chart, Halozyme Therapeutics ranks #1088 out of 1378 companies in the Biotechnology industry, placing it in the top 79%.
Is Halozyme Therapeutics' Cash Ratio too high?
Halozyme Therapeutics' current Cash Ratio of 0.67 is 81% below median its 10-year median of 3.55. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 14.78. The Biotechnology industry median Cash Ratio is 2.96. Halozyme Therapeutics' value of 0.67 is 77.4% below this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #1088 out of 1378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cash Ratio compare to NUVL and KRYS?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #1088 out of 1378 companies for Cash Ratio. This places Halozyme Therapeutics in the lower half of its industry. The industry median Cash Ratio is 2.96. Halozyme Therapeutics' value of 0.67 is 77.4% below this benchmark. Historically, Halozyme Therapeutics' own Cash Ratio has ranged from 0.67 to 14.78 over the past decade. While the company's 10-year median is 3.55 vs. the industry median of 2.96, Halozyme Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Cash Ratio of 0.67 is 77.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Cash Ratio is 0.67, which is 81% below median its own 10-year median of 3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Fairly Valued. The stock's GF Value™ is $97.09, compared to a current price of $98.63 — trading 1.6% above its estimated fair value. The current Cash Ratio is 0.67, which is 81% below median its 10-year median of 3.55 and 77.4% below the Biotechnology industry median of 2.96. Halozyme Therapeutics' overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Cash Ratio is 0.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued.
The current stock price of $98.63 is trading 1.6% above its estimated GF Value™ of $97.09.
GuruFocus considers Halozyme Therapeutics to be Fairly Valued.
Key valuation signals for HALO:
Cash Ratio: 0.67 (81% below median its 10-year median of 3.55)
GF Value™: $97.09 vs. price of $98.63 (1.6% above fair value)
Industry Position: 77.4% below the Biotechnology median (#1088 of 1378)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
